The FDA’s decision not to approve roxadustat follows a 13 to 1 vote last month from the agency’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) indicating that the drug’s benefit-risk profile does not support approval for anemia of CKD in adult NDD patients; CRDAC also voted 12 to 2 against approval in adult …
Will roxadustat be approved?
Roxadustat is currently approved in various countries, including China and Japan, to treat anaemia in these patient populations. The drug is being reviewed by various regulatory agencies, including in the European Union, where it received a positive Committee for Medicinal Products for Human Use (CHMP) opinion.
Is roxadustat approved in Europe?
Roxadustat is approved in EU member states, including the EEA countries, as well as in Japan, China, Chile and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Who owns roxadustat?
(FibroGen China) has received marketing authorization from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of patients with anemia caused by chronic kidney disease (CKD) in patients who are dialysis- …
What is Roxadustat?
Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD).
How do I get Epogen?
This medication is given as an injection under the skin or into a vein as directed by your doctor, usually 1 to 3 times a week. Patients getting this medication before surgery may have a special dosing schedule. Hemodialysis patients should receive this medication by injection into a vein.
What does Astellas Pharma do?
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Who makes roxadustat?
AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in the U.S., China , and other markets in the Americas and in Australia / New Zealand as well as Southeast Asia .
What is roxadustat?
Who makes Roxadustat?
Who developed Roxadustat?
Roxadustat (Ai Rui Zhuo® in China) is an orally administered, small molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by FibroGen, in collaboration with Astellas and AstraZeneca, for the treatment of anaemia in patients with dialysis-dependent chronic kidney disease (CKD), non …
Are Procrit and Epogen the same drug?
Epogen and Procrit are both epoetin alfa, but they are marketed by two different pharmaceutical companies. The FDA approved epoetin alfa in June 1989.
Is AstraZeneca’s Roxadustat safe?
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that promotes erythropoiesis, or red blood cell production. AstraZeneca stated that the safety and efficacy of roxadustat have already been tested in the Phase III programme, which was performed in more than 8,000 patients.
Is Roxadustat approved in Europe?
Roxadustat is approved in a number of countries, including China and Japan, for the treatment of anaemia in CKD in NDD and DD adult patients. It is under regulatory review in other jurisdictions, including in the European Union, where it has recently received a positive CHMP opinion.
Is FibroGen’s Roxadustat approved in the US?
The US Food and Drug Administration (FDA) has declined to approve the new drug application (NDA) for FibroGen’s roxadustat to treat anaemia in chronic kidney disease (CKD) patients. Being developed in alliance with AstraZeneca and Astellas Pharma, roxadustat is an oral inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH).
Will Roxadustat be available for patients with chronic kidney disease (CKD)?
Roxadustat is under regulatory review for the treatment of anaemia of chronic kidney disease (CKD). AstraZeneca and FibroGen are committed to working with the FDA ahead of the meeting and to bringing roxadustat to patients with anaemia of CKD. A date for the advisory committee meeting has not been determined.
